AR032173A1 - Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer - Google Patents
Cripto proteinas y sus variantes como efectores linfocitarios contra el cancerInfo
- Publication number
- AR032173A1 AR032173A1 ARP010104025A ARP010104025A AR032173A1 AR 032173 A1 AR032173 A1 AR 032173A1 AR P010104025 A ARP010104025 A AR P010104025A AR P010104025 A ARP010104025 A AR P010104025A AR 032173 A1 AR032173 A1 AR 032173A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequences
- seq
- polynucleotides
- encoded
- polynucleotide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 8
- 108091033319 polynucleotide Proteins 0.000 abstract 8
- 239000002157 polynucleotide Substances 0.000 abstract 8
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen y reivindican polinucleotidos y aislados de polipéptidos que comprenden secuencias de aminoácidos codificados por dichos polinucleotidos, aplicables en el diagnostico y terapia del cáncer particularmente del cáncer de pulmon, del colon y colorectal. Dichas secuencias de polinucleotidos se seleccionan del grupo consistente de: (a) secuencias formadas por al menos 20 residuos contiguos de una secuencia proporcionada en SEQ ID NO: 1 o 3, sin ser la SEQ ID NO: 1 completa o la SEQ ID NO: 3 completa; (b) secuencias que comprenden SEQ ID NO: 1 o al menos 20 residuos contiguos de la misma y un polinucleotido que codifica una molécula de fusion heterologo; (c) variantes degeneradas de las secuencias de (a) y (b) anteriores. Dichas secuencias de aminoácidos se seleccionan del grupo consistente de: (a) secuencias codificadas por un polinucleotido segun la reivindicacion 1; y (b) secuencias que tienen una identidad de al menos el 70% con una secuencia codificada por un polinucleotido segun la reivindicacion 1; y (c) secuencias que tienen una identidad de al menos el 90% con una secuencia codificada por un polinucleotido segun la reivindicacion 1. Y además - vectores de expresion operables que comprenden dichos polinucleotidos, células transfectadas y células transformadas con dichos vectores y composiciones para el diagnostico, prevencion y/o los tratamientos de las enfermedades mencionadas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0020953.6A GB0020953D0 (en) | 2000-08-24 | 2000-08-24 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
AR032173A1 true AR032173A1 (es) | 2003-10-29 |
Family
ID=9898284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010104025A AR032173A1 (es) | 2000-08-24 | 2001-08-23 | Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer |
Country Status (19)
Country | Link |
---|---|
US (2) | US7439320B2 (es) |
EP (1) | EP1311678A2 (es) |
JP (1) | JP2004506441A (es) |
KR (1) | KR20030045041A (es) |
CN (1) | CN1471579A (es) |
AR (1) | AR032173A1 (es) |
AU (1) | AU2001295498A1 (es) |
BR (1) | BR0113491A (es) |
CA (1) | CA2420087A1 (es) |
CZ (1) | CZ2003537A3 (es) |
GB (1) | GB0020953D0 (es) |
HU (1) | HUP0302824A2 (es) |
IL (1) | IL154533A0 (es) |
MX (1) | MXPA03001634A (es) |
NO (1) | NO20030823L (es) |
NZ (1) | NZ524344A (es) |
PL (1) | PL363005A1 (es) |
WO (1) | WO2002016413A2 (es) |
ZA (1) | ZA200301436B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
GEP20074091B (en) | 2001-04-26 | 2007-04-25 | Biogen Idec Inc | Cripto blocking antibodies and uses thereof |
US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
JP2005520566A (ja) * | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Cripto特異的抗体 |
NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
CN101137673B (zh) | 2005-01-05 | 2013-12-04 | 比奥根艾迪克Ma公司 | Cripto结合分子 |
US8527510B2 (en) | 2005-05-23 | 2013-09-03 | Monster Worldwide, Inc. | Intelligent job matching system and method |
US8195657B1 (en) | 2006-01-09 | 2012-06-05 | Monster Worldwide, Inc. | Apparatuses, systems and methods for data entry correlation |
US8600931B1 (en) | 2006-03-31 | 2013-12-03 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
WO2007127461A2 (en) * | 2006-04-28 | 2007-11-08 | Biogen Idec Ma Inc. | Composition and methods for the detection of cripto-3 |
WO2008040759A1 (en) * | 2006-10-03 | 2008-04-10 | Pharmexa A/S | Method for down-regulation of cripto |
US8645817B1 (en) * | 2006-12-29 | 2014-02-04 | Monster Worldwide, Inc. | Apparatuses, methods and systems for enhanced posted listing generation and distribution management |
US9830575B1 (en) | 2008-04-21 | 2017-11-28 | Monster Worldwide, Inc. | Apparatuses, methods and systems for advancement path taxonomy |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN103313990B (zh) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
KR101995620B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
NZ707534A (en) | 2012-10-12 | 2018-08-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
EA032986B1 (ru) | 2012-12-21 | 2019-08-30 | Медимьюн Лимитед | Пирролобензодиазепины |
AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
BR112015023333A8 (pt) | 2013-03-13 | 2018-04-17 | Medimmune Ltd | pirrolbenzodiazepinas e conjugados dos mesmos |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
KR20160042080A (ko) | 2013-08-12 | 2016-04-18 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
US20170330153A1 (en) | 2014-05-13 | 2017-11-16 | Monster Worldwide, Inc. | Search Extraction Matching, Draw Attention-Fit Modality, Application Morphing, and Informed Apply Apparatuses, Methods and Systems |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
PE20170905A1 (es) | 2014-09-17 | 2017-07-12 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
MA55153A (fr) * | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3544636T (pt) | 2017-02-08 | 2021-05-04 | Medimmune Ltd | Conjugados de anticorpos-pirrolobenzodiazepinas |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
US5633147A (en) * | 1994-03-08 | 1997-05-27 | Human Genome Sciences, Inc. | Transforming growth factor αH1 |
US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
US5834399A (en) * | 1997-12-22 | 1998-11-10 | Eastman Kodak Company | Subbing layer for dye-donor element used in thermal dye transfer |
IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
AU2001264559A1 (en) * | 2000-06-05 | 2001-12-17 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
-
2000
- 2000-08-24 GB GBGB0020953.6A patent/GB0020953D0/en not_active Ceased
-
2001
- 2001-08-20 WO PCT/EP2001/009646 patent/WO2002016413A2/en not_active Application Discontinuation
- 2001-08-20 JP JP2002521508A patent/JP2004506441A/ja active Pending
- 2001-08-20 AU AU2001295498A patent/AU2001295498A1/en not_active Abandoned
- 2001-08-20 CZ CZ2003537A patent/CZ2003537A3/cs unknown
- 2001-08-20 US US10/362,597 patent/US7439320B2/en not_active Expired - Fee Related
- 2001-08-20 IL IL15453301A patent/IL154533A0/xx unknown
- 2001-08-20 NZ NZ524344A patent/NZ524344A/en unknown
- 2001-08-20 MX MXPA03001634A patent/MXPA03001634A/es not_active Application Discontinuation
- 2001-08-20 PL PL01363005A patent/PL363005A1/xx unknown
- 2001-08-20 HU HU0302824A patent/HUP0302824A2/hu unknown
- 2001-08-20 BR BR0113491-4A patent/BR0113491A/pt not_active IP Right Cessation
- 2001-08-20 CN CNA018177336A patent/CN1471579A/zh active Pending
- 2001-08-20 CA CA002420087A patent/CA2420087A1/en not_active Abandoned
- 2001-08-20 KR KR10-2003-7002701A patent/KR20030045041A/ko not_active Application Discontinuation
- 2001-08-20 EP EP01976131A patent/EP1311678A2/en not_active Withdrawn
- 2001-08-23 AR ARP010104025A patent/AR032173A1/es not_active Application Discontinuation
-
2003
- 2003-02-21 NO NO20030823A patent/NO20030823L/no not_active Application Discontinuation
- 2003-02-21 ZA ZA200301436A patent/ZA200301436B/xx unknown
- 2003-04-04 US US10/407,481 patent/US20040138112A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002016413A2 (en) | 2002-02-28 |
US7439320B2 (en) | 2008-10-21 |
HUP0302824A2 (hu) | 2005-05-30 |
EP1311678A2 (en) | 2003-05-21 |
IL154533A0 (en) | 2003-09-17 |
WO2002016413A8 (en) | 2003-02-06 |
US20040054142A1 (en) | 2004-03-18 |
CA2420087A1 (en) | 2002-02-28 |
GB0020953D0 (en) | 2000-10-11 |
NZ524344A (en) | 2004-07-30 |
CN1471579A (zh) | 2004-01-28 |
KR20030045041A (ko) | 2003-06-09 |
ZA200301436B (en) | 2004-05-21 |
JP2004506441A (ja) | 2004-03-04 |
NO20030823D0 (no) | 2003-02-21 |
BR0113491A (pt) | 2003-06-24 |
MXPA03001634A (es) | 2004-09-10 |
WO2002016413A3 (en) | 2002-12-05 |
AU2001295498A1 (en) | 2002-03-04 |
CZ2003537A3 (cs) | 2003-09-17 |
NO20030823L (no) | 2003-04-23 |
US20040138112A1 (en) | 2004-07-15 |
PL363005A1 (en) | 2004-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR032173A1 (es) | Cripto proteinas y sus variantes como efectores linfocitarios contra el cancer | |
AR014514A1 (es) | Un polinucleotido aislado; un polipeptido aislado codificado por dicho polinucleotido; un vector de expresion que comprende dicho polinucleotido; unacelula transformada con dicho vector de expresion; una composicion farmaceutica y una vacuna que comprenden el polipeptido para el tratamiento de cance | |
CO5700785A2 (es) | Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal | |
ES2054878T3 (es) | Expresion de la proapolipoproteina a-i humana. | |
SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
CA2370289A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
AR039003A1 (es) | Composiciones y metodos para alterar el contenido de tocotrienoles | |
AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
AR020066A1 (es) | Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican | |
PE20240915A1 (es) | Composiciones y metodos para tratar la enfermedad de fabry | |
CY2605B2 (en) | Nucleotide sequence coding for a flavin-containingmonooxygenase, corresponding protein and their ap plications in the fields of diagnosis and therapy | |
AR010337A1 (es) | Acido nucleico aislado, molecula de acido nucleico, sonda, vector de expresion recombinante, celula, metodo para producir un polipeptido de h.pylori, metodo para detectar la presencia de un acido nucleico helicobacter, polipeptido de h.pylori aislado, proteina de fusion, formulacion para vacuna | |
DK1237915T3 (da) | Polynucleotid, som kodet for polypeptidet RG1 | |
PE20001287A1 (es) | Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral | |
AR015393A1 (es) | Molecula de polinucleotido aislada, molecula de oligonucleotido que la hibrida, vector de expresion recombinante, celula hospedadora transformada,polipeptido aislado, procedimiento para prepararlo, analogos o derivados del mismo, vacuna que comprende los anteriores, vacuna de combinacion, procedimie | |
DE60120187T2 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
DK1947175T3 (da) | Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf | |
AR029130A1 (es) | Gen enzimatico y sus productos de expresion | |
ATE544779T1 (de) | Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten | |
WO2024123895A3 (en) | A molecular switch to tune the avidity of immune cells to their target | |
AR018100A1 (es) | Polipeptidos que comprenden una parte inmunogenica de un antigeno de m.tuberculosis soluble, y moleculas de adn que codifican dichos polipeptidos, losvectores de expresion que comprenden dichas moleculas de adn, las celulas huesped transformadas con dichos vectores, las composiciones farmaceuticas, | |
PE20241336A1 (es) | Proteina de la capside vp1 modificada aislada del virus adenoasociado de serotipo 9 (aav9), capside y vector basado en la misma | |
AR037054A1 (es) | Composiciones y metodos de diagnostico y terapia de cancer de pulmon | |
AR122260A1 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |